BACKGROUND: Treatment of metastatic castration-resistant prostate cancer (mCRPC) is primarily palliative and patients’ quality of life (QoL) is considered an important treatment goal. Nevertheless, little is known about QoL of mCRPC patients. OBJECTIVES: To assess QoL outcomes in mCRPC patients in Germany. METHODS: 1-year observational, cross-sectional, prospective study conducted in Germany by 37 prostate-cancer (PC) specialised centres. The study included patients with confirmed PC diagnosis and metastatic castration-resistant disease. EQ-5D and FACT-P questionnaires were completed by patients at inclusion visit. Patient characteristics were collected by physicians. Interim results based on 101 of 281 patients in total, are presented. RESULTS: Mean age was 73.2 years. At inclusion, 32.6% had never been treated with chemotherapy (no CT), 36.8% had been treated with chemotherapy previously (past CT) and 30.5% were currently undergoing chemotherapy (ongoing CT). Mean time since PC diagnosis was 7.2 years (respectively 8.7, 6.6 and 4.0 years for no CT, past CT and ongoing CT). 34.0% of patients had metastases at diagnosis. Mean (SD) EQ-5D single index utility score was 0.72 (0.30) (respectively 0.81 (0.27), 0.66 (0.30), 0.64 (0.31) for no CT, past CT and ongoing CT). 67.3% of patients exhibited pain or discomfort, 58.1% problems to perform usual activities, 53.1% mobility problems, 37.7% anxiety/depression troubles and 32.7% self-care problems. Mean (SD) EQ-5D VAS score was 47.8 (23.6). Mean (SD) FACT-P total score was 101.5 (25.2) (respectively 106.0 (27.1), 95.2 (21.6) and 103.5 (26.7) for no CT, past CT and ongoing CT). Mean (SD) subscale scores were: physical well-being: 19.5 (6.6), social/family well-being: 20.6 (5.6), emotional well-being: 17.0 (4.8), functional well-being: 15.7 (6.3) and PC subscale: 28.6 (9.0). CONCLUSIONS: The interim analysis provides first trends on QoL in German mCRPC patients. Final analyses are expected to clarify determinants of QoL and in particular the impact of chemotherapy.